Table 3.
Characteristics | Total |
---|---|
(n = 354) | |
Induction therapy, n (%) | |
Basiliximab | 193 (54.5) |
Antithymocyte globulin | 160 (45.2) |
with i.v. Ig | 6 (1.7) |
Basiliximab + antithymocyte globulin | 1 (0.3) |
Maintenance therapy, n (%) | |
MMF + tacrolimus | 240 (67.8) |
MMF + cyclosporine | 97 (27.4) |
MMF + everolimus | 1 (0.3) |
Tacrolimus + everolimus | 14 (4.0) |
Tacrolimus + azathioprine | 2 (0.6) |
MMF, mycophenolate mofetil.